NOVA Novo Nordisk A/S ADS

NOVO NORDISK 72 HOUR DEADLINE ALERT: APPROXIMATELY 72 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Novo Nordisk A/S – (NVO)

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Novo Nordisk A/S (NYSE: NVO). Investor losses must relate to purchases of the Company’s American Depositary Receipts (“ADRs”) between February 5, 2015 and October 27, 2016. This action is pending in the United States District Court for the District of New Jersey.

What You May Do

If you purchased ADRs of Novo Nordisk and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by March 13, 2017.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
11/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novo Nordisk A/S ADS

Novo Nordisk A/S - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

Novo Nordisk A/S: Key facts and statistics - LTM June 2025

A summary company profile, detailing Novo Nordisk A/S’s business operations and financial highlights.

Novo Nordisk A/S: Acquisition of Akero Therapeutics expands MASH pipel...

The debt-financed transaction will have only a limited effect on Novo Nordisk's leverage.

 PRESS RELEASE

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Be...

NEW YORK--(BUSINESS WIRE)-- , a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See . As detailed below, the complaint...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch